Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.

British journal of clinical pharmacology - 1 Sept 2010

Furuta Takahisa, Iwaki Takayuki, Umemura Kazuo

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Active metabolism of clopidogrel is mainly mediated by CYP2C19. There are genetic differences in the activity of CYP2C19. Therefore, active metabolism of clopidogrel is affected by CYP2C19 genotypes. The main metabolizing enzyme of proton pump inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Clopidogrel
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Proton Pump Inhibitors

Share to Statistics as Topic

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 20716239
DOI: 10.1111/j.1365-2125.2010.03717.x
PMCID: PMC2949911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20716239-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.PMID 20716239Read ↗

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.Semantic proximity Read ↗

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.Semantic proximity Read ↗

Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes.Semantic proximity Read ↗

Genetic and nongenetic factors influencing the response to clopidogrel.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Recent advances in the pharmacogenetics of clopidogrel.Semantic proximity Read ↗

The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.Semantic proximity Read ↗

Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.Semantic proximity Read ↗

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.Semantic proximity Read ↗

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.